Metabolic & Cardiometabolic
PCSK9 inhibitors (evolocumab, alirocumab) decreases LDL cholesterol (~50-60%)
In plain terms: Do PCSK9 inhibitors like evolocumab and alirocumab substantially lower LDL cholesterol?
Strong support Metabolic & Cardiometabolic 💰 Industry COI noted
Part of: 💊 PCSK9 inhibitors
RefutedContestedStrong support
consensus score 1.00
Yes, unequivocally — monoclonal PCSK9 antibodies cut LDL cholesterol by roughly 50-60% on top of statins, one of the most reproducible drug effects in lipidology.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
8 support 0 contradict 0 tested null 0 mixed · 8 sources, 8 independent groups · 2 superseded — pooled inside a review, counted once
The evidence (14)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Robinson 2015 (ODYSSEY LONG TERM) 2015 · N Engl J Med | RCT | supports | high | ODYSSEY LONG TERM (NCT01507831), 78-week randomized double-blind placebo-controlled phase 3 trial: 2,341 patients at high cardiovascular risk with LDL-C >=70 mg/dL, ALL on maximally tolerated statin, randomized 2:1 to alirocumab 150 mg subcutaneously every 2 weeks or placebo. Primary endpoint met: 'At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks.' Note this is a placebo-ADJUSTED difference in percentage points, and an INCREMENTAL effect on top of maximally tolerated statin, not monotherapy. Abstract-grade: arm sizes, achieved absolute LDL and discontinuation rates are not in the text of record. Funded by Sanofi and Regeneron with sponsor employees on the byline. |
| Koren 2014 (MENDEL-2) 2014 · J Am Coll Cardiol | RCT | supports | high | MENDEL-2 (NCT01763827), phase III monotherapy trial, 614 patients randomized 1:1:1:1:2:2 across six arms - oral+SC placebo biweekly or monthly, ezetimibe+SC placebo biweekly or monthly, and evolocumab 140 mg biweekly or 420 mg monthly with oral placebo. Entry required fasting LDL-C >=100 and <190 mg/dl with a Framingham risk score <=10%: untreated, low-risk primary prevention, no statin background. 'Evolocumab treatment reduced LDL-C from baseline, on average, by 55% to 57% more than placebo and 38% to 40% more than ezetimibe (p < 0.001 for all comparisons).' Tolerability: 'Treatment-emergent adverse events (AEs), muscle-related AEs, and laboratory abnormalities were comparable across treatment groups.' Amgen-sponsored (five of the ten authors are Amgen employees). 55-57% sits inside this claim's ~50-60% object band, and because there is no statin background it is the cleanest available read of PCSK9 blockade acting alone - which is also its applicability limit: it does not predict on-statin add-on effect. Read from the PubMed abstract only; trial duration, any explicit blinding statement, the LDL assay method, per-arm n's and the funding paragraph are not in the readable text (blinding is inferable from the matched oral/SC double-dummy allocation but is never stated). |
| Toth 2017 · J Am Heart Assoc. 2017 Oct 2;6(10):e005367 | meta-analysis | supports | moderate | Bayesian network meta-analysis of 15 randomized trials in patients inadequately controlled on moderate- to high-intensity statin: 'PCSK9 inhibitors significantly reduced LDL-C by 54% to 74% versus placebo and 26% to 46% versus ezetimibe.' That 54-74% span runs across BOTH drugs and ALL doses, not evolocumab alone and not by background therapy - evolocumab 140 mg Q2W was the largest single estimate at -74.1% vs placebo (95% CrI -79.81% to -68.58%), alirocumab 75 mg Q2W the smallest at 54%. Quality moderate, not high: 'Amgen sponsored the systematic review and network meta-analysis, which was conducted by Kleijnen Systematic Reviews, Ltd under contract to Amgen' with 5 Amgen employee/stockholder co-authors, 'We could not assess publication bias because there were not enough studies in each direct meta-analysis to generate a funnel plot', and 'Direct meta-analyses suggested that high statistical heterogeneity (I 2 >=70%) was observed for some comparisons.' The class effect is not in doubt here; the sponsor's stake is in the evolocumab-vs-alirocumab comparison, not in whether PCSK9 inhibition lowers LDL. |
| Blais JE 2026 · JACC Adv | observational | tested-null | moderate | Objective, verbatim: 'The aim of the study was to determine the prevalence of adherence to PCSK9 inhibitors in real-world practice across all adherence phases.' 94 studies reviewed, 56 pooled (n = 75,902); every pooled outcome is an adherence proportion — 'Initiation was high at 91.7% (95% CI: 83.6-96.0)', 'At 12 months, persistence was 81.8% (95% CI: 68.2-90.4), and the discontinuation rate was 12.1% (95% CI: 7.4-19.0)'. RCTs were excluded by design: 'RCTs were not included, as our objective was to evaluate adherence in real-world clinical practice rather than in trial participants.' LDL-C is never an outcome: it appears once as an introduction premise attributed to reference 1 — 'Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors profoundly reduce low-density lipoprotein (LDL) cholesterol levels and lower cardiovascular risk' — and thereafter only as a baseline covariate in meta-regression. The paper therefore casts no vote on whether PCSK9 inhibition lowers LDL; off-scope, not tested-null. |
| Sabatine, Giugliano, Wiviott, Raal, Blom, Robinson, Ballantyne, Somaratne, Legg, Wasserman, Scott, Koren, Stein 2015 · N Engl J Med 372(16):1500-1509 | RCT | supports | moderate | OSLER-1 + OSLER-2 combined, n=4,465, median 11.1 months: 'As compared with standard therapy alone, evolocumab reduced the level of LDL cholesterol by 61%, from a median of 120 mg per deciliter to 48 mg per deciliter' (P<0.001). DESIGN LIMIT (why quality is moderate, not high): 'In two open-label, randomized trials' — unblinded, and the comparator is 'standard therapy alone', with no placebo, unlike the blinded parent trials. NOT AN INDEPENDENT COHORT: 'we enrolled 4465 patients who had completed 1 of 12 phase 2 or 3 studies ('parent trials') of evolocumab' — zero new patients; DESCARTES, MENDEL-2, LAPLACE-2 and RUTHERFORD-2 all vote separately on this claim and all four of their lead authors appear on this byline. Read this as durability of an already-counted effect in already-counted people, not as fresh confirmation. |
| Schwartz GG, Steg PG, Szarek M, Bhatt DL, ODYSSEY OUTCOMES Investigators 2018 · N Engl J Med 2018 Nov 29;379(22):2097-2107 | RCT | supports | high | ODYSSEY OUTCOMES (n=18,924 post-ACS, all on high-intensity or maximum-tolerated statin, median follow-up 2.8 y, double-blind placebo-controlled): LDL-C is the trial's titrated target, not a reported result in the readable text - entry required 'a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter)' and 'The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter).' NO achieved LDL-C value and no percent reduction appears anywhere in the available text (abstract only; PMID 30403574 has no PMC deposit - the box's own harvest maps it to 'none'), so the previously recorded '~55% at 4 months' is UNVERIFIED HERE and has been removed rather than repeated: direction and the blinded titration design are anchored, the magnitude that the claim's '~50-60%' band turns on is not. Industry-funded (Sanofi and Regeneron). |
| Raal 2015 (RUTHERFORD-2) 2015 · Lancet | RCT | supports | high | RUTHERFORD-2: evolocumab in 331 heterozygous FH patients on statins lowered LDL 59-66% vs placebo — effective even in genetic hypercholesterolemia. |
| Guedeney 2019 · Eur Heart J | meta-analysis | supports | high | Meta-analysis of 39 alirocumab/evolocumab RCTs (66 478 patients, 150 617 patient-years, mean follow-up 2.3 years). Its stated endpoints are clinical, not lipid: 'Primary efficacy endpoints were all-cause death, cardiovascular death, myocardial infarction (MI), and stroke.' PCSK9 inhibitors lowered MI (RR 0.80, 95% CI 0.74-0.86), ischaemic stroke (RR 0.78, 95% CI 0.67-0.89) and coronary revascularization (RR 0.83, 95% CI 0.78-0.89), while 'the effects of PCSK9 inhibition on all-cause death and cardiovascular death were not statistically significant (P = 0.15 and P = 0.34, respectively).' No pooled LDL-C reduction is reported in the available text, so this paper does not test the LDL-lowering claim. |
| Sabatine, Giugliano, Keech, Honarpour, Wiviott, Murphy, Kuder, Wang, Liu, Wasserman, Sever, Pedersen 2017 · N Engl J Med. 2017 May 4;376(18):1713-1722 | RCT | supports | high | FOURIER (NCT01764633), randomized double-blind placebo-controlled, n=27,564 with atherosclerotic CVD and LDL 70 mg/dL or higher already on statin therapy; evolocumab 140 mg q2w or 420 mg monthly SC vs matching placebo. On-claim result: 'At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter)'. Effect is placebo-adjusted and on top of background statin, so it is the incremental PCSK9 effect, not total lipid lowering. Median follow-up 2.2 years. Funded by Amgen; four co-authors are Amgen employees. |
| Arnaboldi L, Tang Z, Ferri N, Corsini A 2026 · Eur Heart J Suppl | observational | supports | low | Narrative review, no primary data: 'No new data were generated or analysed in support of this research.' It re-reports others' trials, and the LDL-lowering direction it reports is real and large — 'After 24 weeks, enlicitide reduced LDL-C by 55.8% compared with placebo (primary end-point), and two-thirds of patients achieved LDL-C reductions >50%, reaching the recommended target of LDL-C < 55 mg/dL (vs. 1.2% with placebo)'; CORALreef-HeFH gave '−58.2%' for LDL-C, and the cited Masson 2026 meta-analysis '−55.7%'. Quality low: unsystematic, translated from an Italian congress volume, published in a journal supplement, with senior authors funded by AMGEN, Sanofi, MSD and Daiichi-Sankyo. |
| Blom 2014 (DESCARTES) 2014 · N Engl J Med | RCT | supports | high | DESCARTES (NCT01516879), phase 3 double-blind, 901 patients randomized 2:1: evolocumab 420 mg every 4 weeks cut LDL-C by 57.0±2.1% vs placebo at week 52 (P<0.001, primary endpoint by ultracentrifugation), and held across every background stratum — 55.7% on diet alone, 61.6% on atorvastatin 10 mg, 56.8% on atorvastatin 80 mg, 48.5% on atorvastatin 80 mg plus ezetimibe. Amgen-funded. Durable year-long reduction on top of maximal oral therapy. ↩ SUPERSEDED — pooled in the review above, counted once |
| Navarese 2015 · Ann Intern Med | meta-analysis | supports | high | Systematic review + meta-analysis of 24 phase 2/3 RCTs (10,159 patients, search through 4 April 2015): 'treatment with PCSK9 antibodies led to marked reductions in low-density lipoprotein cholesterol levels (mean difference, -47.49% [95% CI, -69.64% to -25.35%]; P < 0.001)' vs no antibody. Wide CI = substantial between-trial heterogeneity (dose/comparator mix); no I2 reported for the lipid endpoint. This is a SYNTHESIS of the same trial pool several other appraisals on this claim report individually, not an independent replication of it. Its prespecified mortality endpoints are off this claim and rare-event ('clinical outcome data are rare'; study-level, not patient-level data). |
| Burnett 2025 · J Cardiovasc Pharmacol | meta-analysis | supports | moderate | Bayesian random-effects network meta-analysis of 20 randomized trials in statin-treated ASCVD/high-risk patients; 'The outcome of interest was percentage change in LDL-C at week 24.' PCSK9 monoclonal antibodies sit at the top of the network: 'This NMA further reaffirmed that inclisiran provided comparable LDL-C reduction versus alirocumab (MD: -1.93% [95% CrI: -8.56 to 4.20]) and evolocumab (MD: 2.00% [95% CrI: -4.58 to 8.60])', while inclisiran itself 'provided superior efficacy in LDL-C lowering compared with ezetimibe and bempedoic acid (MD: -44.24 [95% CrI: -51.84 to -36.70])'. Supports the direction of the claim; the abstract reports only between-drug mean differences, so it does not verify the ~50-60% absolute magnitude. Novartis-authored (inclisiran manufacturer); search closed January 2023. |
| Robinson 2014 (LAPLACE-2) 2014 · JAMA | RCT | supports | high | LAPLACE-2 (NCT01763866), 12-week phase 3, double-blind, placebo- and ezetimibe-controlled: 2,067 randomized to a moderate- or high-intensity statin, then 1,899 re-randomized to add-on evolocumab vs placebo vs ezetimibe. Evolocumab 'reduced LDL-C levels by 66% (95% CI, 58% to 73%) to 75% (95% CI, 65% to 84%) (every 2 weeks) and by 63% (95% CI, 54% to 71%) to 75% (95% CI, 67% to 83%) (monthly) vs placebo at the mean of weeks 10 and 12', taking on-treatment LDL-C to 39-49 mg/dL on moderate-intensity and 33-38 mg/dL on high-intensity statin. Abstract-grade: the trial is ezetimibe-controlled but reports no evolocumab-vs-ezetimibe LDL contrast, so no head-to-head verdict is carried here. ↩ SUPERSEDED — pooled in the review above, counted once |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.